Propranolol is a non-selective -β adrenergic receptor blocker that recently has emerged as a good therapeutic option in IH. In 2008, Leaute-Labreze et al. reported regression of a facial IH in a child who was treated with propranolol for obstructive hypertrophic cardiomyopathy.[25] Ever since there has been a series of publications describing its therapeutic efficacy and side effects.[262728293031323334353637383940] Currently, it is widely used in IH, particularly for complicated and ulcerated IH, and appears to be the best therapeutic modality.[31]